将骨形成蛋白（bone morphogenetic protein, BMPs）与动物胶原蛋白复合，获得具有诱骨活性的骨缺损修复材料是目前植骨材料研究领域的热点。但动物胶原蛋白一方面有引起免疫反应和传播病原体的风险，另一方面因BMPs与胶原蛋白主要以物理吸附作用结合，导致BMPs的缓释效果不理想。本课题在已有类人胶原蛋白（human-like collagen, HLC）研究的基础上，首先利用基因工程技术重组HLC和人骨形成蛋白-2（human BMP-2, hBMP2），构建其原核表达载体，在大肠杆菌中诱导表达具有柔性接头的HLC-hBMP2融合蛋白；进一步揭示融合蛋白释放速率对细胞增殖分化及动物体内诱导成骨的影响，阐明HLC-hBMP2释放速率与其诱骨作用的关系，为构建可充分利用hBMP2的植骨材料提供新的设计思路和理论依据。

Bone morphogenetic proteins (BMPs) can induce ectopic bone formation, and is considered as an optimized candidate to treat bone defects when delivered via a collagen sponge. However, the application and exploitation of animal collagen is restricted due to its potential for immunogenicity and virus contamination. Furthermore, collagen sponge rapidly releases BMP with a high burst phase that is followed by a low sustained phase. Recombinant human-like collagens (HLCs) are similar in structure to human collagen, and have good biocompatibility such as low immunogenicity and little risk from hidden virus. In the proposed study, we will construct a HLC and human bone morphogenetic protein-2 (hBMP-2) complex through recombinant expression of fusion proteins in Escherichia coli. The release rate and the activity of the fusion protein will then be tested via protein concentration test, cell proliferation, cell differentiation and bone defect repair assays. As a novel delivery system for hBMP2, the HLC-hBMP2 fusion protein developed in this study will be valuable for bone defect repair and bone regeneration research.